PVNNF yields 2000000.00% · JNJ yields 2.13%● Live data
📍 PVNNF pulled ahead of the other in Year 1
Combined, PVNNF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PVNNF + JNJ for your $10,000?
P.V. Nano Cell Ltd. engages in developing, manufacturing, marketing, and commercializing conductive inks for digital inkjet conductive printing applications. It develops the Sicrys family of single crystal nano-metric conductive inks; and silver-based Sicrys inks for printed electronics (PE) applications, including photovoltaic devices, printed passive components, circuit boards, mobile phone antennas, 3D printed electronic devices, radio-frequency identification chips, sensors and touchscreens, and other digital PE, as well as printing of windshields in automotive applications. The company also provides copper-based nano-metric inks for mass-production of PE. In addition, it manufactures printing machines, which offer solutions for inkjet print-quality technologies; and provides gold, resistor, and dielectric inks. The company operates in Israel, the United States, Spain, Germany, Holland, Austria, and internationally. P.V. Nano Cell Ltd. was incorporated in 2009 and is headquartered in Migdal HaEmek, Israel.
Full PVNNF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.